Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06242860 · ClinicalTrials.gov registry record · NA

Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease

A NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, sponsored by Eyedetec Medical.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT06242860 is a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease that has completed, run by Eyedetec Medical. The registered enrollment target is 31 participants, below the 99-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06242860, a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye Disease, has completed, sponsored by Eyedetec Medical.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate the Eye Lipid Mobilizer (ELM) for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction. The main questions aim to confirm that 1) the ELM can meet its intended use by validated patient reporting outcomes and 2) to confirm that the ELM device can be used safely by different users within a clinical environment as determined by review of any adverse events related to the use of the device.

Interventions

  • DEVICE ELM

Study Locations (1)

California

  • EYEcenter Optometric - Citrus Heights

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2022-02-08
Est. Completion 2022-03-14
Phase NA

Sponsor

Eyedetec Medical

1 total trials

What the Registry Record Tells You About NCT06242860

The ClinicalTrials.gov registry entry for NCT06242860 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (69% lower). The listed sponsor is Eyedetec Medical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which ELM is the first listed.

NCT06242860 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06242860 about?

NCT06242860 is a clinical study titled "Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease". The goal of this clinical trial is to evaluate the Eye Lipid Mobilizer (ELM) for the treatment of evaporative dry eye disease associated with meibomian gland dysfunction. The main questions aim to confirm that 1) the ELM can meet its intended use by validated patient reporting outcomes and 2) to con...

What is the current status of trial NCT06242860?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2022-02-08. Estimated completion is 2022-03-14.

What conditions does trial NCT06242860 study?

This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye Disease.

What interventions are being tested in trial NCT06242860?

The interventions under investigation include: ELM (DEVICE).

Who is sponsoring clinical trial NCT06242860?

This trial is sponsored by Eyedetec Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06242860 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Meibomian Gland Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.